320 related articles for article (PubMed ID: 32930787)
1. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
Lin AL; Donoghue MTA; Wardlaw SL; Yang TJ; Bodei L; Tabar V; Geer EB
J Clin Endocrinol Metab; 2020 Dec; 105(12):3807-20. PubMed ID: 32930787
[TBL] [Abstract][Full Text] [Related]
2. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
3. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
4. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
5. Aggressive Pituitary Adenomas and Carcinomas.
Ilie MD; Jouanneau E; Raverot G
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):505-515. PubMed ID: 32741485
[TBL] [Abstract][Full Text] [Related]
6. [Aggressive pituitary adenoma and pituitary carcinoma].
Tóth M
Orv Hetil; 2023 Jul; 164(30):1167-1175. PubMed ID: 37516994
[TBL] [Abstract][Full Text] [Related]
7. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
9. Management of Nonfunctioning Recurrent Pituitary Adenomas.
Farrell CJ; Garzon-Muvdi T; Fastenberg JH; Nyquist GG; Rabinowitz MR; Rosen MR; Evans JJ
Neurosurg Clin N Am; 2019 Oct; 30(4):473-482. PubMed ID: 31471054
[TBL] [Abstract][Full Text] [Related]
10. Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients.
Mortini P; Barzaghi R; Losa M; Boari N; Giovanelli M
Neurosurgery; 2007 Jun; 60(6):993-1002; discussion 1003-4. PubMed ID: 17538372
[TBL] [Abstract][Full Text] [Related]
11. Aggressive pituitary tumors.
Chatzellis E; Alexandraki KI; Androulakis II; Kaltsas G
Neuroendocrinology; 2015; 101(2):87-104. PubMed ID: 25571935
[TBL] [Abstract][Full Text] [Related]
12. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review.
Cooper O; Bonert V; Liu NA; Mamelak AN
Front Endocrinol (Lausanne); 2021; 12():725014. PubMed ID: 34867776
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers.
Tampourlou M; Ntali G; Ahmed S; Arlt W; Ayuk J; Byrne JV; Chavda S; Cudlip S; Gittoes N; Grossman A; Mitchell R; O'Reilly MW; Paluzzi A; Toogood A; Wass JAH; Karavitaki N
J Clin Endocrinol Metab; 2017 Jun; 102(6):1889-1897. PubMed ID: 28323946
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
16. Recurrent pituitary adenomas.
Marguth F; Oeckler R
Neurosurg Rev; 1985; 8(3-4):221-4. PubMed ID: 4033962
[TBL] [Abstract][Full Text] [Related]
17. [Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options].
Maïza JC; Caron P
Ann Endocrinol (Paris); 2009 Sep; 70 Suppl 1():S12-9. PubMed ID: 19878763
[TBL] [Abstract][Full Text] [Related]
18. Multimodal therapy in aggressive pituitary tumors.
Iglesias P; Magallón R; Mitjavila M; Rodríguez Berrocal V; Pian H; Díez JJ
Endocrinol Diabetes Nutr (Engl Ed); 2020; 67(7):469-485. PubMed ID: 31740190
[TBL] [Abstract][Full Text] [Related]
19. Atypical pituitary adenoma: a clinicopathologic case series.
Rutkowski MJ; Alward RM; Chen R; Wagner J; Jahangiri A; Southwell DG; Kunwar S; Blevins L; Lee H; Aghi MK
J Neurosurg; 2018 Apr; 128(4):1058-1065. PubMed ID: 28598278
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas.
Minniti G; Paolini S; Rea MLJ; Isidori A; Scaringi C; Russo I; Osti MF; Cavallo L; Esposito V
J Neurooncol; 2020 Aug; 149(1):123-130. PubMed ID: 32632895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
